Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrion received a milestone payment of $2m
Subscribe to our email newsletter
Novo Nordisk has initiated its first Phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a $2m payment to Merrion whose Gipet technology is used in the formulation of NN1952.
The company said that the aim of the trial, which is conducted in Germany, is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 in healthy volunteers and people with type 1 and type 2 diabetes. Results from the trial, which is planned to enrol about 80 people, are expected to be reported in the first half of 2011.
NN1952 has been designed to address some of the key challenges relating to oral insulin delivery. Furthermore, it utilises the Gipet formulation technology from Merrion Pharmaceuticals to facilitate insulin absorption from the gut.
The company said that in November 2008, Merrion entered into a development and license agreement to develop and commercialise oral formulations of Novo Nordisk’s proprietary insulin analogues, using Merrion’s proprietary Gipet technology (Gastrointestinal Permeation Enhancement Technology). This is the first development milestone achieved by Merrion under this agreement.
John Lynch, chief executive of Merrion, said: “The $2m milestone payment, which we have achieved by meeting all necessary deadlines, is an extremely positive development for Merrion. This is a major programme for Merrion and we are determined to ensure that our highly motivated team of specialists maximises the likelihood of success for Novo Nordisk’s oral insulin candidates.”
Peter Kurtzhals, senior vice president and head of diabetes research at Novo Nordisk, said: “We still have many challenges to overcome, and it is far too early to say whether or when oral insulin will become an alternative to insulin injections. However, I am encouraged by the progress our research and development teams have made during the past two years, and which has led us to this important milestone.”